Generate Biomedicines, Inc.
GENB
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -61.45M | -41.69M | |||
| Total Depreciation and Amortization | 3.27M | 3.41M | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 8.44M | 2.54M | |||
| Change in Net Operating Assets | -30.65M | -17.44M | |||
| Cash from Operations | -80.39M | -53.18M | |||
| Capital Expenditure | -3.78M | -751.00K | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -256.15M | 76.28M | |||
| Cash from Investing | -259.93M | 75.53M | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -1.12M | -2.65M | |||
| Issuance of Common Stock | 372.51M | 483.00K | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | 21.97M | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | 7.50M | 750.00K | |||
| Cash from Financing | 378.89M | 20.56M | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 38.57M | 42.92M | |||